Immune checkpoint blockade (ICB) therapies have revolutionized cancer treatment, yet many tumors remain resistant. Now, ...

Dr. Vincent Ma discussed the most recent and notable treatment updates for patients with high-risk and advanced melanoma.

Liver cancer is a malignant tumor characterized by high incidence and mortality rates worldwide. According to the report by the World Health Organization, ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

A teacher who was told it was “highly unlikely” she had cancer because “young people have lumpy boobs” was later diagnosed ...

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

A glucose-sensitive nanovaccine delivers CRISPR to tumors, silences immune-suppressing genes, and activates a targeted immune response against cancer.

Austen Mary Fields has a cancer that strikes fewer than 1 in 3 million people. Her family has gone to clinics in Mexico for ...

Modulating the gut microbiome may improve immunotherapy outcomes in solid tumors including melanoma, RCC, and NSCLC, offering ...

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased ...